About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Efficacy and Safety of Grass-SPIRE Registration Study

NCT02795273·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Circassia Limited

Age

12–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Clinical history of grass pollen-induced allergic rhinitis with or without conjunctivitis for at least 2 years
Score of ≤ 21 on RCAT questionnaire
Rye grass specific IgE of ≥ 0.7 kU/L
Positive skin prick test to Rye grass whole allergen extract

You may not be if

History or findings of significant disease
Asthma requiring GINA Step 3 or higher treatment
History of severe drug allergy, severe angioedema or systemic allergic reaction
Course of short-duration allergy-specific immunotherapy or more than 3 months treatment with long-duration allergen immunotherapy within 5 years
Contraindications for administration of epinephrine

The record

StatusWithdrawn

PhasePhase 2–3

Taking part0

StartedMay 2016

UpdatedJun 23, 2016

Conditions

Rhinitis Conjunctivitis

Where2

Canton, Ohio, United States
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, United States

Clareo Health | Efficacy and Safety of Grass-SPIRE Registration Study